Ysios BioFund I FCR 3
3 · Kala Pharmaceuticals, Inc. · Filed Jul 19, 2017
Insider Transaction Report
Form 3
Ysios BioFund I FCR
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (666,670 underlying)Series C Preferred Stock
→ Common Stock (62,721 underlying)
Footnotes (2)
- [F1]The Series B Convertible Preferred Stock is convertible into Common Stock on a 5.2083-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]The Series C Convertible Preferred Stock is convertible into Common Stock on a 5.2083-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.